Literature DB >> 23197271

Considerations in the surgical management of ovarian cancer in the elderly.

Carrie Langstraat1, William A Cliby.   

Abstract

Elderly patients with advanced epithelial ovarian cancer present a complex treatment dilemma. On the one hand, patients can be treated with primary debulking surgery to achieve the ideal oncologic outcomes but at the expense of risk of surgical morbidity and mortality. On the other hand, they can be treated with alternative, less morbid approaches, reducing toxicity, but sacrificing the survival benefits of low residual disease by surgical cytoreduction. Retrospective studies have attempted to identify risk factors for poor surgical outcome. Although there is no consensus to define "elderly" or "frail," current evidence identifies age, performance status, nutritional status, and surgical complexity as major risk factors for surgical morbidity. Accepting the shortcomings of these retrospective data, candidates for primary debulking surgery can be assessed for risk of surgical morbidity. Age is likely a contributor to morbidity, particularly in the face of comorbid conditions. Clinicians should strive to treat elderly patients with a standard approach of primary debulking surgery and adjuvant chemotherapy when healthy and in the absence of other risk factors. Elderly patients with the following are poor surgical candidates and an alternative treatment approach should be considered: poor nutritional status (characterized by serum albumin <3.0 g/dL), or poor performance status (ASA ≥3), and stage IV disease. Several of these factors are modifiable by treating the underlying cancer. These patients should be treated with two to three cycles of neoadjuvant chemotherapy and reassessed for surgical debulking. Patients with improvement in their nutritional or performance status can undergo interval debulking with the goal to resect all visible disease.

Entities:  

Mesh:

Year:  2013        PMID: 23197271     DOI: 10.1007/s11864-012-0216-2

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  53 in total

1.  Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes.

Authors:  Michele Peiretti; Robert E Bristow; Ignacio Zapardiel; Melissa Gerardi; Vanna Zanagnolo; Roberto Biffi; Fabio Landoni; Luca Bocciolone; Giovanni Damiano Aletti; Angelo Maggioni
Journal:  Gynecol Oncol       Date:  2012-04-30       Impact factor: 5.482

2.  Causes of postoperative mortality after surgery for ovarian cancer.

Authors:  C G Gerestein; R A M Damhuis; M de Vries; A Reedijk; C W Burger; G S Kooi
Journal:  Eur J Cancer       Date:  2009-07-15       Impact factor: 9.162

3.  The implications of age and comorbidity on survival following epithelial ovarian cancer: summary and results from a Centers for Disease Control and Prevention study.

Authors:  Cynthia D O'Malley; Sarah J Shema; Rosemary D Cress; Katrina Bauer; Amy R Kahn; Maria J Schymura; Jennifer M Wike; Sherri L Stewart
Journal:  J Womens Health (Larchmt)       Date:  2012-07-20       Impact factor: 2.681

4.  Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction.

Authors:  Kate A McLean; Chirag A Shah; Sara A Thompson; Heidi J Gray; Ron E Swensen; Barbara A Goff
Journal:  Gynecol Oncol       Date:  2010-04-27       Impact factor: 5.482

5.  The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.

Authors:  Dennis S Chi; Oliver Zivanovic; Kimberly L Levinson; Valentin Kolev; Jae Huh; Joseph Dottino; Ginger J Gardner; Mario M Leitao; Douglas A Levine; Yukio Sonoda; Nadeem R Abu-Rustum; Carol L Brown; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2010-07-06       Impact factor: 5.482

6.  Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

Authors:  Dennis S Chi; Corinna C Franklin; Douglas A Levine; Faina Akselrod; Paul Sabbatini; William R Jarnagin; Ronald DeMatteo; Elizabeth A Poynor; Nadeem R Abu-Rustum; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2004-09       Impact factor: 5.482

7.  Primary cytoreductive surgery for epithelial ovarian cancer.

Authors:  N F Hacker; J S Berek; L D Lagasse; R K Nieberg; R M Elashoff
Journal:  Obstet Gynecol       Date:  1983-04       Impact factor: 7.661

8.  Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Michael J Sundborg; G Scott Rose; Peter G Rose; Stephen C Rubin; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-11-19       Impact factor: 44.544

9.  Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.

Authors:  Giovanni D Aletti; Sean C Dowdy; Karl C Podratz; William A Cliby
Journal:  Am J Obstet Gynecol       Date:  2007-12       Impact factor: 8.661

10.  Impact of age on survival of patients with ovarian cancer.

Authors:  M Markman; J L Lewis; P Saigo; T Hakes; S Rubin; W Jones; B Reichman; J Curtin; R Barakat; L Almadrones
Journal:  Gynecol Oncol       Date:  1993-05       Impact factor: 5.482

View more
  2 in total

1.  Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status.

Authors:  Hisamitsu Takaya; Hidekatsu Nakai; Kosuke Murakami; Takako Tobiume; Ayako Suzuki; Masaki Mandai; Noriomi Matsumura
Journal:  Int J Clin Oncol       Date:  2018-03-23       Impact factor: 3.402

2.  Age is associated with prognosis in serous ovarian carcinoma.

Authors:  Fei Deng; Xia Xu; Mengmeng Lv; Binhui Ren; Yan Wang; Wenwen Guo; Jifeng Feng; Xiaoxiang Chen
Journal:  J Ovarian Res       Date:  2017-06-12       Impact factor: 4.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.